Skip to content

Other ways to search: Events Calendar | UTHSC News

Institute for Biomarker and Molecular Therapeutics

IBMT Vision:

The Institute for Biomarker and Molecular Therapeutics (IBMT) is a research enterprise focused on developing newer biomarkers and molecular level therapeutic modalities for chronic diseases. IBMT will be a designated institutional research resource, which will be focused on cutting- edge scientific research, enabling access to high-end equipment, advanced techniques and specialized expertise. It incorporates the efforts and programs of both basic science researchers and clinical investigators across the entire continuum of translational research. IBMT will establish partnerships with industry, academic institutions, and philanthropists; raise research funds; conduct novel research and develop new diagnostics, drugs, and immunotherapies.  It will support the focus areas across the UTHSC System, integrate with the other institutes, centers and core facilities, and perform research in the areas outlined in the Strategic Plan for Strengthening Research.

IBMT Mission:

The Institute for Biomarker and Molecular Therapeutics (IBMT) is a research enterprise focused on developing newer biomarkers and molecular level therapeutic modalities for chronic diseases such as, but not limited to, cancers, HIV/AIDS, stroke and cardiovascular disorders. In the process of achieving its primary objectives, the IBMT will serve as a resource for teaching pharmacy, medical, graduate, and other multi-disciplinary students to generate future workforce in the proposed areas.

Research Focus:

The focus of the IBMT will be development of animal models, drugs, diagnostics and immunotherapies for chronic health conditions.  The IBMT thematic research includes investigational research, pre-clinical laboratory research, cell lines and animal model discovery research and regulated clinical trial research.

Initiatives:

The structure of IBMT includes four primary Initiatives. These are: [1] investigational research, [2] preclinical research, [3] translational research and [4] clinical research in the area of human chronic diseases.

 

ibmt

May 26, 2022